Peripheral and central signals in the control of eating in normal, obese and binge-eating human subjects

British Journal of Nutrition

Volumn 92, Issue SUPPL. 1, 2004, Pages

  Hellström, Per M ^a   Geliebter, Allan ^b   Näslund, Erik ^c   Schmidt, Peter T ^a   Yahav, Eric K ^b   Hashim, Sami A ^b   Yeomans, Martin R ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c DANDERYD HOSPITAL   (Sweden)

^d UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

Hormones; Obesity; Signalling systems

Indexed keywords

ADIPONECTIN; AGOUTI RELATED PROTEIN; ALPHA MELANOCORTIN STIMULATING HORMONE; ANTIOBESITY AGENT; CHOLECYSTOKININ; GHRELIN; GLUCAGON LIKE PEPTIDE 1; INSULIN; LEPTIN; MELANOCORTIN; NEUROPEPTIDE Y; OREXIN; PEPTIDE YY; RESISTIN; SEROTONIN 1A AGONIST; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; APPETITE; ARCUATE NUCLEUS; BINGE EATING DISORDER; BRAIN STEM; CALORIC INTAKE; CENTRAL NERVOUS SYSTEM; ENERGY BALANCE; ENERGY EXPENDITURE; FEEDING BEHAVIOR; GASTROINTESTINAL TRACT; HORMONE ACTION; HUMAN; HUNGER; HYPOTHALAMUS NUCLEUS; METABOLIC REGULATION; NERVE CELL NETWORK; OBESITY; PERIPHERAL NERVOUS SYSTEM; REVIEW; SATIETY; SIGNAL TRANSDUCTION; SOLITARY TRACT NUCLEUS; VAGUS NERVE;

ADIPOCYTES; APPETITE DEPRESSANTS; APPETITE REGULATION; BRAIN; EATING; GASTROINTESTINAL TRACT; HOMEOSTASIS; HORMONES; HUMANS; HYPERPHAGIA; MALE; OBESITY; PERIPHERAL NERVOUS SYSTEM; SATIATION; SIGNAL TRANSDUCTION;

AGOUTI;

EID: 3042681566     PISSN: 00071145     EISSN: None     Source Type: Journal    
DOI: 10.1079/BJN20041142     Document Type: Review

References (126)

1. Adam JA, Menheere PP, van Dielen FM, Soeters PB, Buurman WA & Greve JW (2002) Decreased plasma orexin-A levels in obese individuals. Int J Obes Relat Metab Disord 26, 274-276.
2. Adami GF, Meneghelli A & Scopinaro N (1999) Night eating and binge-eating disorder in obese patients. Int J Eat Disord 25, 335-338.
3. Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Fujimiya M, Katsuura G, Makino S, Fujino MA & Kasuga M (2001) A role of ghrelin in neuroendocrine and behavioral responses to stress in mice. Neuroendocrinology 74, 143-147.
4. Ballinger A, McLoughlin L, Medback S & Clark M (1995) Cholecystokinin is a satiety hormone in humans at physiological concentrations. Clin Sci 89, 375-381.
5. Batterham RL (2002) Gut hormone PYY3-36 physiologically inhibits food intake. Nature 418, 650-654.
6. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA & Bloom SR (2003) Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349, 941-948.
7. Batterham RL, Cowley MA, Small CJ, et al. (2002) Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418, 650-654.
8. Bell GI, Santerre RF & Mullenbach GT (1983) Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302, 716-718.
9. Berg AH, Combs TP & Scherer PE (2002) ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 13, 84-89.
10. Bloom SR (1997) Glucagon-like peptide-1 and satiety. Nature 385, 214.
11. Branson R, Potoczna N, Kral JG, Lentes KU, Hoehe MR & Horber FF (2003) Binge eating as a major phenotype of melanocortin 4 receptor gene mutations. N Engl J Med 348, 1096-1103.
12. Bray GA (2000) Afferent signals regulating food intake. Proc Nutr Soc 59, 373-384.
13. Broberger C, Holmberg K, Kuhar MJ & Hokfelt T (1999) Cocaine- and amphetamine-regulated transcript in the rat vagus nerve: a putative mediator of cholecystokinin-induced satiety. Proc Natl Acad Sci USA 96, 13506-13511.
14. Broberger C, Johansen J, Johansson C, Schalling M & Hokfelt T (1998) The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. Proc Natl Acad Sci USA 95, 15043-15048.
15. Brolin RE (1992) Critical analysis of results: weight loss and quality of data. Am J Clin Nutr 55, 577S-581S.
16. Buchan AM, Polak JM, Solcia E, Capella C, Hudson D & Pearse AG (1978) Electron immunohistochemical evidence for human intestinal I cells as the source of CCK. Gut 19, 403-407.
17. Burdyga G, Lal S, Spiller D, et al. (2003) Localization of orexin-1 receptors to vagal afferent neurons in the rat and humans. Gastroenterology 124, 129-139.
18. Chamorro S, Della-Zuana O, Fauchere JL, Feletou M, Galizzi JP & Levens N (2002) Appetite suppression based on selective inhibition of NPY receptors. Int J Obes Relat Metab Disord 26, 281-298.
19. Clement K, Dina C, Basdevant A, Chastang N, Pelloux V, Lahlou N, Berlan M, Langin D, Guy-Grand B & Froguel P (1999) A sib-pair analysis study of 15 candidate genes in French families with morbid obesity: indication for linkage with islet 1 locus on chromosome 5q. Diabetes 48, 398-402.
20. Cummings DE & Foster KE (2003) Ghrelin-leptin tango in bodyweight regulation. Gastroenterology 124, 1532-1535.
21. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE & Weigle DS (2001) A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50, 1714-1719.
22. De Zwaan M, Mitchell JE, Raymond NC & Spitzer RL (1994) Binge eating disorder: clinical features and treatment of a new diagnosis. Harv Rev Psychiatry 1, 310-325.
23. Flegal KM, Carroll MD, Ogden CL & Johnson CL (2002) Prevalence and trends in obesity among US adults, 1999-2000. J Am Med Assoc 288, 1723-1727.
24. Flint A, Raben A, Astrup A & Holst JJ (1998) Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101, 515-520.
25. Flint A, Raben A, Rehfeld JF, Holst JJ & Astrup A (2000) The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes 24, 288-298.
26. French SJ, Murray B, Rumsey RD, Sepple CP & Read NW (1993) Is cholecystokinin a satiety hormone? Correlations of plasma cholecystokinin with hunger, satiety and gastric emptying in normal volunteers. Appetite 21, 95-104.
27. Fuxe K, Tinner B, Caberlotto L, Bunnemann B & Agnati L (1997) NPY Y1 receptor-like immunoreactivity exists in a sub-population of β-endorphin immunoreactive nerve cells in the arcuate nucleus: a double immunolabelling analysis in the rat. Neurosci Lett 225, 49-52.
28. Geliebter A (1988) Gastric distension and gastric capacity in relation to food intake in humans. Physiol Behav 44, 665-668.
29. Geliebter A (2002) Weight loss and plasma ghrelin levels. N Engl J Med 347, 1379-1381.
30. Geliebter A & Hashim SA (2001) Gastric capacity in normal, obese, and bulimic women. Physiol Behav 74, 743-746.
31. Geliebter A, Melton PM, McCray RS, Gallagher DR, Gage D & Hashim SA (1992) Gastric capacity, gastric emptying, and test-meal intake in normal and bulimic women. Am J Clin Nutr 56, 656-661.
32. Geliebter A, Westreich S, Pierson RN & Van Itallie TB (1986) Extra-abdominal pressure alters food intake, intragastric pressure, and gastric emptying rate. Am J Physiol 250, R549-R552.
33. Geliebter A, Yahav E, Gluck M & Hashim SA (2004) Gastric capacity, test meal intake, and appetitive hormones in binge-eating disorder. Physiol Behav (In Press).
34. Geracioti TD & Liddle RA (1988) Impaired cholecystokinin secretion in bulimia nervosa. N Engl J Med 319, 683-688.
35. Grill HJ & Norgren R (1978) Chronically decerebrate rats demonstrate satiation but not bait-shyness. Science 201, 267-269.
36. Gutzwiller JP, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J & Beglinger C (1999a) Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 276, R1541-R1544.
37. Gutzwiller JP, Göke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R, Conen D & Beglinger C (1999b) Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44, 81-86.
38. Hagan MM (2002) PeptideYY: a key mediator of orexigenic behavior. Peptides 23, 377-382.
39. Hagan MM, Rushing PA, Pritchard LM, Schwartz MW, Strack AM, Van Der Ploeg LH, Woods SC & Seeley RJ (2000) Long-term orexigenic effects of AgRP-(831-32) involve mechanisms other than melanocortin receptor blockade. Am J Physiol Regul Integr Comp Physiol 279, R47-R52.
40. Hahn TM, Breininger JF, Baskin DG & Schwartz MW (1998) Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat Neurosci 1, 271-272.
41. Hewson G, Leighton RG & Hughes J (1988) The cholecystokinin receptor antagonist L364,718 increases food intake in the rat by attenuation of the action of endogenous cholecystokinin. Br J Pharmacol 93, 79-84.
42. Heymsfield SB, Greenberg AS, Fujioka K, et al. (1999) Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. J Am Med Assoc 282, 1568-1575.
43. Hill JO & Peters JC (1998) Environmental contributions to the obesity epidemic. Science 280, 1371-1374.
44. Holst JJ (1997) Enteroglucagon. Annu Rev Physiol 59, 257-271.
45. Hotta K, Funahashi T, Arita Y, et al. (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20, 1595-1599.
46. Hu E, Liang P & Spiegelman BM (1996) AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271, 10697-10703.
47. Hug C & Lodish HF (2002) Diabetes, obesity, and Acrp30/adiponectin. Biotechniques 33, 654, 656, 658 passim.
48. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML & Ulusoy NB (1997) Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 273, G920-G927.
49. Jin SL, Han VK, Simmons JG, Towle AC, Lauder JM & Lund PK (1988) Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 271, 519-532.
50. Kersten S, Mandard S, Tan NS, Escher P, Metzger D, Chambon P, Gonzalez FJ, Desvergne B & Wahli W (2000) Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J Biol Chem 275, 28488-28493.
51. Kim I, Kim HG, Kim H, Kim HH, Park SK, Uhm CS, Lee ZH & Koh GY (2000) Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosis. Biochem J 346, 603-610.
52. Kirchgessner AL (2002) Orexins in the brain-gut axis. Endocrol Rev 23, 1-15.
53. Kirchgessner AL & Liu M (1999) Orexin synthesis and response in the gut. Neuron 24, 941-951.
54. Kissileff HR, Pi-Sunyer FX, Thornton J & Smith GP (1981) C-terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr 34, 154-160.
55. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H & Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656-660.
56. Komaki G, Matsumoto Y, Nishikata H, Kawai K, Nozaki T, Takii M, Sogawa H & Kubo C (2001) Orexin-A and leptin change inversely in fasting non-obese subjects. Eur J Endocrinol 144, 645-651.
57. Kreymann B, Ghatei MA, Burnet P, Williams G, Kanse S, Diani AR & Bloom SR (1989) Characterization of glucagon-like peptide-1-(73-6)amide in the hypothalamus. Brain Res 502, 325-331.
58. Lambert PD, Wilding PH, Ghatei MA & Bloom SR (1994) A role for GLP-1-(73-6)NH2 in the central control of feeding behaviour. Digestion 54, 360-361.
59. Lieverse RJ, Jansen JBMJ, Zwan A, Samson L, Masclee AAM & Lamers CBHW (1993) Satiety effects of a physiological dose of cholecystokinin in humans. Gut 36, 176-179.
60. Londos C, Gruia-Gray J, Brasaemle DL, Rondinone CM, Takeda T, Dwyer NK, Barber T, Kimmel AR & Blanchette-Mackie EJ (1996) Perilipin: possible roles in structure and metabolism of intracellular neutral lipids in adipocytes and steroidogenic cells. Int J Obes Relat Metab Disord 20, Suppl. 3, S97-S101.
61. Long SJ, Sutton JA, Amaee WB, Giouvanoudi A, Spyrou NM, Rogers PJ & Morgan LV (1999) No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man. Br J Nutr 81, 273-279.
62. Lovshin J & Drucker DJ (2000) New frontiers in the biology of GLP-2. Regul Pept 90, 27-32.
63. MacDougald OA & Mandrup S (2002) Adipogenesis: forces that tip the scales. Trends Endocrinol Metab 13, 5-11.
64. Matsubara M, Maruoka S & Katayose S (2002) Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 147, 173-180.
65. Mercer JG & Lawrence CB (1992) Selectivity of cholecystokinin (CCK) receptor antagonists, MK-329 and L-365,260, for axonally-transported CCK binding sites on the rat vagus nerve. Neurosci Lett 137, 229-231.
66. Morley JE, Levine AS, Grace M & Kneip J (1985) Peptide YY (PYY), a potent orexigenic agent. Brain Res 341, 200-203.
67. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K & Matsukura S (2001) A role for ghrelin in the central regulation of feeding. Nature 409, 194-198.
68. Näslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rössner S & Hellström PM (1999a) Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23, 304-311.
69. Näslund E, Bogefors J, Skogar S, Grybäck P, Jacobsson H, Holst JJ & Hellström PM (1999b) GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 277, R910-R916.
70. Näslund E, Ehrström M, Ma J, Hellström PM & Kirchgessner AL (2002) Localization and effects of orexin on fasting motility in the rat duodenum. Am J Physiol 282, G470-G479.
71. Näslund E, Grybäck P, Backman L, Jacobsson H, Holst JJ, Theodorsson E & Hellström PM (1998a) Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying. Dig Dis Sci 43, 945-952.
72. Näslund E, Gutniak M, Skogar S, Rossner S & Hellström PM (1998b) Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 68, 525-530.
73. Näslund E, King N, Mansten S, Adner S, Holst JJ, Gutniak M & Hellström PM (2004) Prandial subcutaneous injuctions of glucagon-like peptide-1 cause weight loss in obsess human subjects. Br J Nutr 91, 439-446.
74. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Örskov C, Ritzel R & Schmiegel WH (1997) Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273, E981-E988.
75. Nowak KW, Mackowiak P, Switonska MM, Fabis M & Malendowicz LK (2000) Acute orexin effects on insulin secretion in the rat: in vivo and in vitro studies. Life Sci 66, 449-454.
76. O'Rahilly S (2003) Leptin: defining its role in humans by the clinical study of genetic disorders. Nutr Rev 60, 30-34.
77. Ørskov C (1992) Glucagon-like peptide-1, a new hormone of the enteroinsular axis. Diabetologia 35, 701-711.
78. Otto B, Cuntz U, Fruehauf E, Wawarta R, Folwaczny C, Riepl RL, Heiman ML, Lehnert P, Fichter M & Tschop M (2001) Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 145, 669-673.
79. Ouedraogo R, Näslund E & Kirchgessner AL (2003) Glucose regulates the release of orexin-a from the endocrine pancreas. Diabetes 52, 111-117.
80. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M & Scherer PE (2003) Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 278, 9073-9085.
81. Poeschla B, Gibbs J, Simansky KJ, Greenberg D & Smith GP (1993) Cholecystokinin-induced satiety depends on activation of 5-HT1C receptors. Am J Physiol 264, R62-R64.
82. Porte D, Baskin DG & Schwartz MW (2002) Leptin and insulin action in the central nervous system. Nutr Rev 60, S20-S29.
83. Ranganath L, Norris F, Morgan L, Wright J & Marks V (1999) Inhibition of carbohydrate-mediated glucagon-like peptide-1 (73-6)amide secretion by circulating non-esterified fatty acids. Clin Sci 96, 335-342.
84. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R & Marks V (1996) Attenuated GLP-1 secretion in obesity: cause or consequence. Gut 38, 916-919.
85. Raybould HE (1998) Does your gut taste? Sensory transduction in the gastrointestinal tract. News Physiol Sci 13, 275-280.
86. Read N, French SA & Cunningham K (1994) The role of the gut in regulating food intake in man. Nutr Rev 52, 1-10.
87. Reidelberger RD, Varga G & Solomon TE (1991) Effects of selective cholecystokinin antagonists L364,718 and L365,260 on food intake in rats. Peptides 12, 1215-1221.
88. Reubi JC, Waser B, Laderach U, Stettler C, Friess H, Halter F & Schmassmann A (1997) Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach. Gastroenterology 112, 1197-1205.
89. Ritter RC, Covasa M & Matson CA (1999) Cholecystokinin: proofs and prospects for involvement in control of food intake and body weight. Neuropeptides 33, 387-399.
90. Sakurai T, Amemiya A, Ishii M, et al. (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573-585.
91. Sanaka M, Koike Y, Yamamoto T, Mineshita S, Yamaoka S, Hirama S, Tanaka H, Kuyama Y & Yamanaka M (1997) A reliable and convenient parameter of the rate of paracetamol absorption to measure gastric emptying rate of liquids. Int J Clin Pharmacol Ther 35, 509-513.
92. Sanaka M, Kuyama Y & Yamanaka M (1998) Guide for judicious use of the paracetamol absorption technique in a study of gastric emptying rate of liquids. J Gastroenterol 33, 785-791.
93. Scherer PE, Williams S, Fogliano M, Baldini G & Lodish HF (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270, 26746-26749.
94. Schmidt PT, Näslund E, Grybäck P, Jacobsson H, Hartmann B, Holst JJ & Hellström PM (2003) Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. Regul Pept 116, 21-25.
95. Schwartz GJ, McHugh PR & Moran TH (1993) Gastric loads and cholecystokinin synergistically stimulate rat gastric vagal afferents. Am J Physiol 265, R872-R876.
96. Shapiro L & Scherer PE (1998) The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 8, 335-338.
97. Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M, Nozoe S, Hosoda H, Kangawa K & Matsukura S (2002) Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 87, 240-244.
98. Shimizu I, Hirota M, Ohboshi C & Shima K (1987) Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. Endocrinology 121, 1076-1082.
99. Sobhani I, Bado A, Vissuzaine C, et al. (2000) Leptin secretion and leptin receptor in the human stomach. Gut 47, 178-183.
100. Sobhani I, Buyse M, Goiot H, Weber N, Laigneau JP, Henin D, Soul JC & Bado A (2002) Vagal stimulation rapidly increases leptin secretion in human stomach. Gastroenterology 122, 259-263.
101. Sørensen LB, Flint A, Raben A, Hartmann B, Holst JJ & Astrup A (2003) No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. Int J Obes 27, 450-456.
102. Stellar E (1954) The physiology of motivation. Psychol Rev 61, 5-22.
103. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS & Lazar MA (2001) The hormone resistin links obesity to diabetes. Nature 409, 307-312.
104. Takaya K, Ariyasu H, Kanamoto N, et al. (2000) Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 85, 4908-4911.
105. Tang-Christensen M, Larsen PJ, Göke R, Fink-Jensen A, Jessop DS, Moller M & Sheikh SP (1996) Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 271, R848-R856.
106. Tang-Christensen M, Larsen PJ, Thulesen J, Romer J & Vrang N (2000) The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 6, 802-807.
107. Tansey JT, Sztalryd C, Gruia-Gray J, et al. (2001) Perilipin ablation results in a lean mouse with aberrant adipocyte lipolysis, enhanced leptin production, and resistance to diet-induced obesity. Proc Natl Acad Sci USA 98, 6494-6499.
108. Toft-Nielsen MB, Madsbad S & Holst JJ (1999) Continuous subcutaneous infusion of glucagon-like peptide-1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22, 1137-1143.
109. Tolessa T, Gutniak M, Holst JJ, Efendic S & Hellström PM (1998) Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 43, 2284-2290.
110. Trayhurn P & Beattie JH (2001) Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 60, 329-339.
111. Tsai CH, Hill M & Drucker DJ (1997) Biological determinants of intestinotrophic properties of GLP-2. Am J Physiol 272, G662-G668.
112. Tsao TS, Lodish HF & Fruebis J (2002) ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol 440, 213-221.
113. Tschop M, Smiley DL & Heiman ML (2000) Ghrelin induces adiposity in rodents. Nature 407, 908-913.
114. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E & Heiman ML (2001) Circulating ghrelin levels are decreased in human obesity. Diabetes 50, 707-709.
115. Turton MD, O'Shea D, Gunn I, et al. (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69-72.
116. Ukkola O & Santaniemi M (2002) Adiponectin: a link between excess adiposity and associated comorbidities? J Mol Med 80, 696-702.
117. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J & Holst JJ (1993) Truncated GLP-1 (proglucagon 781-07-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38, 665-673.
118. Wettergren A, Wøjdemann M & Holst JJ (1998) Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 275, G984-G992.
119. Wettergren A, Wøjdemann M, Meisner S, Stadil F & Holst JJ (1997) The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 40, 597-601.
120. Wikberg JE, Muceniece R, Mandrika I, Prusis P, Lindblom J, Post C & Skottner A (2000) New aspects on the melanocortins and their receptors. Pharmacol Res 42, 393-420.
121. Wøjdemann M, Wettergren A, Hartmann B & Holst JJ (1998) Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 33, 828-832.
122. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA & Bloom SR (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86, 5992.
123. Yanovski SZ (1993) Binge eating disorder: current knowledge and future directions. Obes Res 1, 306-324.
124. Yanovski SZ (1995) Biological correlates of binge-eating. Addict Behav 20, 705-712.
125. Yeo GS, Farooqi IS, Aminian S, Halsall DJ, Stanhope RG & O'Rahilly S (1998) A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet 20, 111-112.
126. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L & Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425-432.